A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Sponsor and Collaborators
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
+1(800)340-6843
Investigator
Novartis Pharmaceuticals
ClinicalTrials.gov Identifier
NCT01473901
Please login or register first to view this content.
You’ve read {{metering-count}} of {{metering-total}} articles this month.
We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.
{{login-button}} {{register-button}}
Want to view more content from Cancer Therapy Advisor?
Register now at no charge to access unlimited clinical news, full-length features, case studies, conference coverage, and more.
{{login-button}} {{register-button}}
Please login or register first to view this content.